TELCON RF PHARMACEUTICAL. Inc.

TELCON RF PHARMACEUTICAL. Inc.

KKRX:200230
2,125.00
KRW
-20.00
(-0.93%)
-4,720.84EPS
17.34BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
37,340.47
38,275.11
15,321.9
14,992.94
15,856.67
20,245.98
17,087.25
10,443.41
11,615.53
7,077.46
8,755.29
8,627.98
8,998.41
10,806.26
Basic EPS, GAAP
6,316.35
4,391.52
186.92
-2,129.71
-6,335.22
-4,825.55
-17,846.46
-12,886.12
-7,090.06
-10,702.48
3,353.46
-5,997.25
-2,388.3
-3,057.56
Free Cash Flow per Basic Share
9,263.06
313.54
1,069.88
-18,886.35
-21,798.76
-6,105.64
1,280.78
-571.69
-1,894.54
-744.32
-731.28
-855.86
280.76
8.23
Dividend per Share
800.63
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
12,081.76
23,194.79
23,615.38
30,105.64
39,927.24
50,435.93
35,360.37
28,138.32
28,758.49
20,881.52
24,277.35
18,583.97
15,836.3
10,255.92
Tangible Book Value per Share
11,978.29
23,016.58
23,475.71
15,069.84
14,982
34,396.11
24,149.03
18,232.99
20,609.41
14,953.57
19,318.17
14,379.85
13,466.82
7,316.63
Basic Weighted Avg Shares
1
2
2
2
3
3
3
3
3
4
4
4
5
6
Sales/Revenue/Turnover
46,639
58,756
28,543
29,840
41,149
57,708
52,478
33,141
37,841
27,830
36,307
37,865
43,162
61,784
Operating Margin (%)
21.14
13.73
-1
-27.14
-30.88
-13.65
5.96
-6.31
-7.24
-14.6
2.66
-0.19
1.66
0.62
Depreciation Expense
225
428
542
1,330
2,168
4,116
4,432
4,397
4,200
4,281
4,244
4,507
4,824
5,904
Net Income, GAAP
7,889
6,741
348
-4,239
-16,440
-13,755
-54,810
-40,893
-23,098
-42,084
13,906
-26,320
-11,456
-17,481
Effective Tax Rate (%)
21.93
20.59
44.84
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
16.92
11.47
1.22
-14.2
-39.95
-23.83
-104.44
-123.39
-61.04
-151.22
38.3
-69.51
-26.54
-28.29
Working Capital
19,080
39,375
37,514
14,418
-18,574
-712
17,990
-50,664
-22,756
-11,202
-1,935
-43,709
11,475
-8,336
LT Debt
- -
- -
- -
9,242
4,168
- -
1,758
2,574
1,301
728
403
590
1,433
3,819
Total Equity
22,507
43,209
43,992
82,362
134,496
155,452
113,125
91,475
106,608
84,135
104,945
83,135
108,818
99,484
Return on Invested Capital (%)
- -
17.8
-0.35
- -
- -
- -
- -
- -
- -
- -
0.79
- -
- -
- -
Return on Capital (%)
- -
19.37
0.8
- -
- -
- -
- -
- -
- -
- -
11.73
- -
- -
- -
Return on Common Equity (%)
- -
20.52
0.8
-7.79
-19.05
-10.51
-41.23
-40.25
-23.34
-44.14
14.75
-28.11
-11.97
-25.21

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
32,835
38,513
59,328
LT Borrowings
- -
- -
700
LT Finance Leases
1,433
1,310
3,119
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
62,827
56,524
17,342

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
57,735
63,847
71,665
Cash, Cash Equivalents & STI
32,125
30,842
36,578
Accounts Receivable, Net
8,100
8,291
11,701
Inventories
5,123
4,973
15,775
Total Current Liabilities
46,259
51,500
80,001
Payables & Accruals
- -
- -
- -
ST Debt
32,835
38,513
59,328
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15%
6.06%
30.89%
Free Cash Flow
-219.42%
15.85%
-135.85%
Net Income, GAAP
-121.28%
-88.02%
-56.48%
Sales/Revenue/Turnover
7.32%
7.29%
13.99%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,036
8,827
7,163
13,839
37,865
2025
9,984
10,030
9,825
13,322
43,162
2026
9,700
28,937
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-16,902.91
-22,779.83
6,766.55
-2,736.83
-5,997.25
2025
-1,094.51
-1,345.22
-1,382.63
1,437.83
-2,388.3
2026
-1,673.68
-1,949
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Ji-Hun Kim
Full Time Employees
133
Sector
Producer manufacturing
Industry
Industrial machinery
Address
54, Gongse-ro Yongin-si South Korea 17086
IPO Date
Nov 24, 2014
Business
TELCON RF PHARMACEUTICAL. Inc. operates in two distinct business areas: radio frequency (RF) communications equipment and pharmaceuticals. The company engineers, produces, and distributes a global range of RF coaxial connectors, couplers, distributors, arresters, and integrated cable assemblies utilized in wireless communication systems, including 5G, as well as in automotive, medical, and military sectors. Furthermore, its pharmaceutical and biotechnology division manufactures and supplies various finished medicinal products, such as liquids, tablets, pills, and capsules, which now generate the majority of its overall revenue. Established in 1999 as Telcon Co., Ltd., the company maintains its headquarters in Yongin-si, South Korea.